314 related articles for article (PubMed ID: 9455804)
1. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
3. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
5. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
6. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
7. Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement.
Festuccia C; Angelucci A; Gravina G; Eleuterio E; Vicentini C; Bologna M
Exp Cell Res; 2002 Oct; 280(1):1-11. PubMed ID: 12372334
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
9. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
11. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.
Farina AR; Coppa A; Tiberio A; Tacconelli A; Turco A; Colletta G; Gulino A; Mackay AR
Int J Cancer; 1998 Mar; 75(5):721-30. PubMed ID: 9495240
[TBL] [Abstract][Full Text] [Related]
13. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
14. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice.
Billström A; Hartley-Asp B; Lecander I; Batra S; Astedt B
Int J Cancer; 1995 May; 61(4):542-7. PubMed ID: 7759160
[TBL] [Abstract][Full Text] [Related]
15. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Festuccia C; Giunciuglio D; Guerra F; Villanova I; Angelucci A; Manduca P; Teti A; Albini A; Bologna M
Oncol Res; 1999; 11(1):17-31. PubMed ID: 10451028
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator.
Tiberio A; Farina AR; Tacconelli A; Cappabianca L; Gulino A; Mackay AR
Int J Cancer; 1997 Nov; 73(5):740-8. PubMed ID: 9398056
[TBL] [Abstract][Full Text] [Related]
17. Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation.
Brunner G; Reimbold K; Meissauer A; Schirrmacher V; Erkell LJ
Exp Cell Res; 1998 Mar; 239(2):301-10. PubMed ID: 9521847
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Unlü A; Leake RE
Int J Biol Markers; 2003; 18(2):147-51. PubMed ID: 12841684
[TBL] [Abstract][Full Text] [Related]
19. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
20. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion.
Jarrard DF; Blitz BF; Smith RC; Patai BL; Rukstalis DB
Prostate; 1994; 24(1):46-53. PubMed ID: 8290389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
